3 results
Approved WMOPending
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Approved WMOWill not start
To compare the antiproteinuric effects of sacubitril/valsartan (ARNI) and valsartan (ARB).
Approved WMOPending
To evaluate the efficacy of darvadstrocel in combined remission at Week 24 for the treatment of complex perianal fistula in pediatric subjectswith CD aged 4 to <18 years.